Board of Directors
Ruben King-Shaw Jr., Chairman of the Board
Ruben King-Shaw Jr. has three decades of executive leadership experience in the healthcare technology and private equity sectors. He currently serves on the board of US Retina of Denver and is Chief Strategy Officer of Steward Health Care Systems, LLC. He has held executive positions with Neighborhood Health Partnership, Inc. and JMH Health Plan. He recently served on the board of Cotiviti Holdings, Inc. and was Lead Director of Athenahealth; Independent Living Systems, and WellCare Health Plans, Inc. Mr. King-Shaw served on the Obama Administration’s Medicare Program Advisory and Oversight Committee, and was COO and deputy administrator of the Centers for Medicare and Medicaid Services (CMS) managing a federal budget of $600 billion, during the administration of President George W. Bush, and was a senior advisor to the Secretary of the U.S. Treasury for health care tax policies. Mr. King-Shaw earned a Bachelor of Science degree in Industrial and Labor Relations from Cornell University. He earned his Master of Health Service Administration and his Master of International Business degree from Florida International University. He also completed advanced studies in Corporate Governance at the Harvard Business School.
William Yuan, Chairman Emeritus
William Yuan was most recently Chairman and CEO of Fortress Hill Holdings, an Asian-based investment banking firm and has more than 23 years of global finance experience and has advised companies including Amgen Corp., Biogen, GE Capital, Warner Brothers Studios, and Fox News. He also has guided such leading Asian institutions as Sina.com, Shanghai Petrochemicals, Jinlia Pharmaceutical and Tsingtao Beer Corp. In 1995, Mr. Yuan led Merrill Lynch Asset Management Asia, and managed a $488 billion portfolio. Simultaneously, he was chairman and portfolio manager of the $1.2 billion AmerAsia Hedge Fund. In 1993, he founded and served as the managing director of the Corporate Institutional Services Group at Merrill Lynch Asset Management. Prior to that, Mr. Yuan was at Morgan Stanley Smith Barney’s Portfolio Management Corp. and was co-head of the Capital Markets Derivative team, and Chairman of the Technology Investment Management and Executive Policy Committee. He began his career at Goldman Sachs in 1983 as an investment banker in mergers & acquisitions. Mr. Yuan is a member of the International Who’s Who of Finance, Technology, Media and Telecom. He holds a Bachelor of Science degree in Economics from Cornell University and attended Harvard University’s John F. Kennedy School as a Mason Fellow.
Robert Davidson is CURE’s CEO. Prior to his role at CURE Pharmaceutical, Robert Davidson served as President and Chief Executive Officer of InnoZen Inc., Chief Executive Officer of Gel Tech LLC, Chief Executive Officer of Bio Delivery Technologies Inc., and has served on multiple corporate boards. Mr. Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has worked with brands such as Chloraseptic™, Suppress™, as well as Pediastrip™, a private label electrolyte oral thin film sold in major drug store chains. Mr. Davidson received his B.S. degree with a concentration in Biological Life Sciences. He holds a Masters Certificate in Applied Project Management from Villanova University, a Masters of Public Health from American Military University, Virginia and a Masters in Health and Wellness from Liberty University, Virginia. Davidson also completed his Post Graduate Studies at the University of Cambridge with letter of commendation.
Nancy Duitch joined CURE Pharmaceutical as the CEO of wholly owned subsidiary, The Sera Labs, which she founded and sold to CURE Pharmaceutical in September 2020. She continues to lead The Sera Lab as its CEO and has added the roles of Chief Strategic Officer and Board member of CURE Pharmaceutical. Ms. Duitch is an entrepreneur and leader in the consumer products industry and has built successful global branding campaigns that have generated more than $3 billion in consumer product sales for many well-known and beloved national and international brands, including Ab Roller, Ab Trainer, Biotopical Skin Care, Bun & Thigh Max, Ab Revolutionizer, Ultimate Lean Routine, My Place, and The Eyes Have it by Donna Mills. Sera Labs has redefined the sectors of health, wellness, and beauty by creating science-backed, proprietary formulations that use exceptional ingredients, including CBD. The Sera Labs’ more than 20 products are sold under the brand names Sera Labs®, SeraRelief™ and Seratopical™. Prior to founding The Sera Labs, Ms. Duitch held various executive management and consulting positions with companies including Pep Boys, Spa Formula Cosmetics, Kent & Spiegel Marketing, Vertical Branding and VisionWorx. She also co-founded The C.A.R.E Foundation in 1995 to raise awareness about, and help fight, sudden death in children and young adults.
John K. Bell, FCA, FCPA, ICD.D
John K. Bell brings more than 40 years of experience to CURE Pharmaceutical. He is a managing partner at Onbelay Capital Inc., a private equity and investment firm based in Cambridge, Canada. Mr. Bell has sat on a number of public boards, most recently with DelMar Pharmaceuticals (Nasdaq: DMPI), before its acquisition by Kintara Therapeutics. He also was the founder and CEO of Shred-Tech, Inc and was the owner and CEO of Polymer Technologies Inc. Mr. Bell previously served as chairman and principal shareholder of fleet management company BSM Technologies Inc. (TSX-V) and was CEO and director of ATS Automation ((OTCMKTS:ATSAF) ).. Mr. Bell serves as Chairman of the Board of Canopy Rivers and Canopy Growth and is on the Board of the Royal Canadian Mint. Mr. Bell is also a philanthropist who has contributed to and provided leadership for numerous organizations including Cambridge Memorial Hospital, Waterloo Regional Police, Waterloo Region Prosperity Council, and Crohn’s and Colitis Canada and the Stratford festival. Mr. Bell earned his bachelors degree from the Ivy Business School at Western University, Canada. He earned the ICD.D designation by the Institute of Corporate Directors as a graduate of the ICD-Rotman Directors Education Program.
Lauren Chung, Ph.D
Lauren Chung, Ph. D is the founder and CEO of MINLEIGH LLC, which focuses on identifying, evaluating and partnering with companies for investments and strategic, operational, and commercial opportunities. Dr. Chung has more than 20 years of healthcare investment management, investment banking, and advisory and currently is a venture partner at Yozma Group Asia headquartered in South Korea. Previously, Dr. Chung was a Managing Director in Healthcare Research at WestPark Capital and co-founded Tokum Capital Management, a global healthcare fund, which merged with Perella Weinberg Partners. Prior to that, Dr. Chung managed healthcare investment portfolios at RBR Capital, Kingdon Capital, and Pequot Capital. Earlier in her career, she was a recognized research scientist conducting cutting edge research in neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital. Dr. Chung has published many leading peer-reviewed scientific journals. She currently is lead independent director of Todos Medical Ltd. (OTCQB: TOMDF). Dr. Chung holds a Ph.D. in Neuropathology from Columbia University-College of Physicians & Surgeons, and earned a BA with honors in Biochemistry and Economics from Wellesley College. She holds a Corporate Director Certificate from Harvard Business School.
Anya Goldin, J.D.
Anya Goldin has more than 25 years of experience in corporate finance, capital markets, M&A, private equity, venture capital and commercial transactions. She currently advises companies on strategic and business issues, complex transactions, particularly in venture capital, private equity and technology sectors, as well as corporate restructurings and multijurisdictional disputes. Previously, Ms. Goldin was the Vice President and General Counsel of Sistema JSFC (LSE: SSA), the largest Russian diversified holding company. Previously, she was a Managing Partner at Latham & Watkins where she led 11 IPOs of Russian issuers on the NYSE and LSE. Ms. Goldin has been a board member of 12 public and private companies in Europe, Russia, and the UK. She also currently serves as the Vice Chair of the Board of Directors of Redline Capital Management, a Luxembourg private equity fund. She is on the Advisory Board of the California private equity fund, Lumia Capital, and is on the Board of Trustees of Westmark School, and the Board of Berkeley Law Alumni’s L.A. Chapter. Ms. Goldin has been named a Lawyer’s Lawyer in The Global Law & Business, Partner of the Month by The Lawyer magazine, and ranked as one of the Top-50 businesswomen in Russia by The Company business magazine. She is a member of the State Bar of California. She holds a BA in Mass Communications from the University of California Berkeley, as well as a JD from University of California Berkeley School of Law.
Joshua Held has broad experience in corporate development, deal origination, complex deal structures, legal planning, business succession planning, new brand build-outs, and media planning. His diverse expertise spans finance, law, sales, and marketing. . He is responsible for launching Chemistry Holdings, Inc. a formulation technology company that creates innovative, sustainable delivery systems for a variety of industries. Mr. Held is also the founder and CEO of Made by Science, which works to develop next-generation delivery systems for cannabis product manufacturers and sellers by eliminating common problems in efficacy, formulation, onset, dosage, and labeling. Mr. Held was previously Vice President, Private Wealth Management at JP Morgan. He received his Bachelor of Arts from the California State University, Long Beach.
Gene Salkind, MD
Dr. Salkind is a board certified neurological surgeon. He has had numerous faculty, hospital and administrative appointments at major hospitals in northeastern Philadelphia.. As a prolific pharmaceutical investor, Dr. Salkind’s previous successful investments include Intuitive Surgical, Pharmacyclics, which was acquired by AbbVie, and Centocor, which was acquired by Johnson & Johnson.. Dr. Salkind currently sits on the board of DermTech (Nasdaq: DMTK), a global leader in non-invasive dermatological molecular diagnostics. Salkind has completed various residencies, fellowships and postgraduate training at Abington Memorial hospital, The Graduate Hospital, Veteran’s Administration Hospital, Pennsylvania Hospital, Children’s Hospital of Philadelphia, and the Hospital of the University of Pennsylvania. He received his Medical Degree from Temple University School of Medicine and his Bachelor of Arts from the University of Pennsylvania.
Mr. Szapiro is co-founder, managing partner and principal of Entourage Effect Capital, an investment firm focused on the cannabis industry. Mr. Szapiro also co-founded AFS Acceptance LLC, and served as President and CEO and oversaw the businesses’ expansion into 30 states until its sale in 2015 to Credito Real SAB de CV, which is Mexico’s largest non-bank financial institution and is listed in the Mexican Stock Exchange. Previously, Mr. Szapiro was a director of business development for GovWorks, Inc, an internet start-up in the e-government sector. Earlier in his career, Mr. Szapiro was an analyst for Bassini, Playfair + Associates, a $1.2 billion emerging markets private equity firm. Mr. Szapiro also serves as Member of the Board of Directors of Conception Nurseries, Promociones Fantasticas SAS, PathogenDx, and One Last Harrah. He also serves on the non-profit boards of KovodFund.org and is an Advisor for the Alliance for Education. Mr. Szapiro earned his Bachelors in Business Administration from The Wharton School at the University of Pennsylvania.